| Jennifer Mai-khoi Nguyen, AA | |
|
1500 Citywest Blvd Ste 300, Houston, TX 77042-2549 | |
| (713) 620-4000 | |
| (716) 458-4229 |
| Full Name | Jennifer Mai-khoi Nguyen |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology Assistant |
| Experience | 9 Years |
| Location | 1500 Citywest Blvd Ste 300, Houston, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225417959 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367H00000X | Anesthesiologist Assistant | 1996 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Hermann - Texas Medical Center | Houston, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| U S Anesthesia Partners Of Texas, Pa | 7315850351 | 2379 |
News Archive
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today the initiation of two clinical trials with OSI-906, the Company's potential first-in-class, oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor. The first study is a Phase III, multi-center study that will evaluate the use of OSI-906 for patients with locally advanced or metastatic adrenocortical carcinoma (ACC).
UC Irvine researchers have demonstrated that basketballs and volleyballs can spread potentially dangerous germs among players. Their findings may bring a new awareness to athletes, coaches, trainers and parents regarding safe sanitation practices for athletes.
Graceway Pharmaceuticals, LLC, a portfolio company of GTCR Golder Rauner, LLC, today announced that the company has acquired from Gilead Sciences, Inc. the worldwide license, including related regulatory filings and intellectual properties, to Gilead's investigational molecule, GS 9191, for topical use. GS 9191 is an anti-proliferative agent that works by inhibiting cellular DNA synthesis, leading to the induction of apoptosis, or programmed cell death.
Type 2 diabetes (T2D) may affect treatment options for patients who have both coronary artery disease (CAD) and T2D.
For some women, planning a family can be the first step towards one of life's most rewarding experiences. But a study led by Ryerson University researchers has found strong evidence that some HIV-positive women feel that they are being judged negatively by their healthcare providers for wanting to become moms and feel stigmatized by their physicians due to their medical condition.
› Verified 8 days ago
| Entity Name | U S Anesthesia Partners Of Texas, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548208564 PECOS PAC ID: 7315850351 Enrollment ID: O20031106000563 |
News Archive
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today the initiation of two clinical trials with OSI-906, the Company's potential first-in-class, oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor. The first study is a Phase III, multi-center study that will evaluate the use of OSI-906 for patients with locally advanced or metastatic adrenocortical carcinoma (ACC).
UC Irvine researchers have demonstrated that basketballs and volleyballs can spread potentially dangerous germs among players. Their findings may bring a new awareness to athletes, coaches, trainers and parents regarding safe sanitation practices for athletes.
Graceway Pharmaceuticals, LLC, a portfolio company of GTCR Golder Rauner, LLC, today announced that the company has acquired from Gilead Sciences, Inc. the worldwide license, including related regulatory filings and intellectual properties, to Gilead's investigational molecule, GS 9191, for topical use. GS 9191 is an anti-proliferative agent that works by inhibiting cellular DNA synthesis, leading to the induction of apoptosis, or programmed cell death.
Type 2 diabetes (T2D) may affect treatment options for patients who have both coronary artery disease (CAD) and T2D.
For some women, planning a family can be the first step towards one of life's most rewarding experiences. But a study led by Ryerson University researchers has found strong evidence that some HIV-positive women feel that they are being judged negatively by their healthcare providers for wanting to become moms and feel stigmatized by their physicians due to their medical condition.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer Mai-khoi Nguyen, AA Po Box 840853, Dallas, TX 75284-0853 Ph: (972) 233-1999 | Jennifer Mai-khoi Nguyen, AA 1500 Citywest Blvd Ste 300, Houston, TX 77042-2549 Ph: (713) 620-4000 |
News Archive
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today the initiation of two clinical trials with OSI-906, the Company's potential first-in-class, oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor. The first study is a Phase III, multi-center study that will evaluate the use of OSI-906 for patients with locally advanced or metastatic adrenocortical carcinoma (ACC).
UC Irvine researchers have demonstrated that basketballs and volleyballs can spread potentially dangerous germs among players. Their findings may bring a new awareness to athletes, coaches, trainers and parents regarding safe sanitation practices for athletes.
Graceway Pharmaceuticals, LLC, a portfolio company of GTCR Golder Rauner, LLC, today announced that the company has acquired from Gilead Sciences, Inc. the worldwide license, including related regulatory filings and intellectual properties, to Gilead's investigational molecule, GS 9191, for topical use. GS 9191 is an anti-proliferative agent that works by inhibiting cellular DNA synthesis, leading to the induction of apoptosis, or programmed cell death.
Type 2 diabetes (T2D) may affect treatment options for patients who have both coronary artery disease (CAD) and T2D.
For some women, planning a family can be the first step towards one of life's most rewarding experiences. But a study led by Ryerson University researchers has found strong evidence that some HIV-positive women feel that they are being judged negatively by their healthcare providers for wanting to become moms and feel stigmatized by their physicians due to their medical condition.
› Verified 8 days ago
James Nast Trahan, AA Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 1500 Citywest Blvd Ste 300, Houston, TX 77042 Phone: 713-620-4000 | |
Caitlyn Marie Kohake, Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 6720 Bertner Ave, Houston, TX 77030 Phone: 823-355-2666 | |
Robert Sean Mcneill, AA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 1500 Citywest Blvd, Ste. 300, Houston, TX 77042 Phone: 713-620-4000 Fax: 713-458-4229 | |
Aleena A Gillani, AA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 1500 Citywest Blvd Ste 300, Houston, TX 77042 Phone: 972-233-1999 Fax: 972-233-3666 | |
Logan Patrick Fettig, Anesthesiologist Assistant Medicare: Not Enrolled in Medicare Practice Location: 6720 Bertner Ave, Houston, TX 77030 Phone: 832-355-2666 | |
Joseph Grant Shafer, AA-C Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 6414 Fannin St, #g125, Houston, TX 77030 Phone: 713-500-6930 Fax: 713-500-5484 | |
Sarah P Her, AA-S Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 1500 Citywest Blvd, Ste. 300, Houston, TX 77042 Phone: 713-620-4000 Fax: 713-458-4229 |